《新股消息》三葉草生物(02197.HK)今日起招股 入場費6,818.02元
生物技術公司三葉草生物(02197.HK)公佈在港上市計劃,擬全球發售1.5億股,其中10%於本港公開發售。招股價介乎每股12.8元至13.5元,每手500股,入場費6,818.02元。今日起至週四(28日)招股,預料11月5日起上市買賣。
聯席保薦人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人爲高盛及中金公司,聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人爲高盛、中金公司及瑞信。
該公司爲一家處於臨牀試驗階段的全球性生物技術公司,致力於爲傳染性疾病以及癌症及自身免疫性疾病開發新型疫苗及生物治療候選產品。公司主要產品於各治療領域的適應症分別爲COVID-19、惡性腹水及強直性脊柱炎。公司成爲COVID-19疫苗開發企業並已創制出核心產品之一的SCB-2019以應對SARS-CoV-2引起的COVID-19疫情。公司亦已開發出另一款核心產品SCB-808,用於治療風溼性疾病。截至最後實際可行日期,公司的在研產品亦包括正在開發中的其他九種候選產品。
公司在是次上市引入9名基石投資者,合共認購1.385億美元等值股份,其中Orbimed Funds認購2,500萬美元,HHLR認購2,200萬美元,淡馬錫認購2,000萬美元,Rock Springs Capital認購1,900萬美元,Oceanpine Capital及Athos Capital分別認購1,500萬美元,Springhill Fund認購1,000萬美元,Superstring認購750萬美元,Toroa認購500萬美元。
以招股價中位數13.15元計,公司預計集資淨額18.37億元,其中65%用於核心產品及相關產品的研發、生產及商業化;22.5%用於管線中其他產品的研發、生產及商業化;其餘12.5%用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.